Therapeutic Implications of Germline Testing in Patients With Advanced Cancers.

ABSTRACT:

Purpose

Tumor mutational profiling is increasingly performed in patients with advanced cancer. We determined the extent to which germline mutation profiling guides therapy selection in patients with advanced cancer.

Methods

Patients with cancer undergoing tumor genomic profiling were prospectively consented for germline cancer predisposition gene analysis (2015-2019). In patients harboring germline likely pathogenic or pathogenic (LP/P) alterations, therapeutic actionability was classified using a precision oncology knowledge base. Patients with metastatic or recurrent cancer receiving germline genotype-directed therapy were determined.

Results

Among 11,947 patients across > 50 malignancies, 17% (n = 2,037) harbored a germline LP/P variant. By oncology knowledge base

SUBMITTER: Stadler ZK 

PROVIDER: S-EPMC8376329 | biostudies-literature | 2021 Aug

REPOSITORIES: biostudies-literature